Immunotherapy and targeted radiation for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial combines immunotherapy with a special type of radiation that spares healthy lymph nodes, aiming to boost the body's immune response against the tumor. It is for patients with certain types of head and neck cancer that have not spread too far and can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of head and neck cancer (squamous cell carcinoma) that is either in the oral cavity or the oropharynx (back of the throat) and is not caused by HPV.
- Your cancer is considered advanced (large tumor and/or spread to lymph nodes) and can be surgically removed.
- Your tumor has a CPS score of at least 1, which means it shows some sign that immunotherapy might help.
- You are in generally good health (able to care for yourself, up and about more than 50% of waking hours).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.